STADA Arzneimittel AG / Corporate Action/Issue of Debt
14.04.2010 16:19
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
STADA Arzneimittel AG today on April 14, 2010, successfully placed a bond
with a volume of EUR 350 million. STADA intends to use the proceeds from
the emission for general business purposes.
The bond has a term of five years with an annual interest rate of 4.00%.
The issue price amounts to 99.987%. The denomination is EUR 1,000. It is
planned to authorize the bond for the Luxembourg Securities Market. The
identification numbers are: WKN: A1DAGK, ISIN: XS0503278847, Common Code:
050327884.
The bond was placed both at institutional investors and private investors
in more than 15 countries. The order book for the emission was more than
seven times oversubscribed. The joint lead managers for this transaction
are Commerzbank Aktiengesellschaft, Deutsche Bank AG, DZ BANK AG and The
Royal Bank of Scotland plc. Deutsche Apotheker- und Ãrztebank eG, HSBC
Trinkaus & Burkhardt AG, WestLB AG and Bankhaus Lampe KG act as co-lead
managers.
Additional information:
STADA Arzneimittel AG / Corporate Communications / StadastraÃe 2-18 /
61118 Bad Vilbel, Germany / Phone: +49 (0) 6101 603-113 /
Fax: +49 (0) 6101 603-506 / E-mail: communications@stada.de
Or visit us in the Internet at www.stada.com.
*************************
For information regarding the securities mentioned in this corporate news,
please refer to the respective securities prospectus dated 13 April 2010,
published on the website of Luxemburg Stock Exchange (www.boerse.lu).
Nothing in this corporate news constitutes an offer of securities, an
invitation to subscribe for securities, any advice or other service in
relation to the securities, nor does it qualify as a contractual or other
obligation in relation to the securities. In particular, the securities
referred to in this corporate news have not been, and will not be,
registered under the U.S. Securities Act of 1933, as amended. The
securities may not be offered or sold within the United States or to, or
for the account or benefit of, U.S. Persons (as defined in Regulation S
under the Securities Act). Information contained in this corporate news may
not be forwarded or distributed to any person or address in the United
States.
14.04.2010 16:19 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv at |[![CDATA[|[a href="http://www.dgap-medientreff.de"|]www.dgap-medientreff.de|[/a|]]]|] and |[![CDATA[|[a href="http://www.dgap.de"|]www.dgap.de|[/a|]]]|]
---------------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
StadastraÃe 2-18
61118 Bad Vilbel
Deutschland
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard), Düsseldorf;
Freiverkehr in Berlin, Hannover, München, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: STADA: STADA Arzneimittel AG successfully places EUR 350 million bond
| Source: EQS Group AG